Asthma cure may be ready in 5 years after scientists discover root cause

Scientists claim to have found what causes the respiratory disease, which could finally pave the way for a cure

<a href="http://www.shutterstock.com/pic-124057978/stock-photo-woman-having-asthma-using-the-asthma-inhaler-for-being-healthy.html" target="_blank">Ashtma patient</a> image via Shutterstock
Press Trust of India London
Last Updated : Apr 24 2015 | 10:52 AM IST
In a first, scientists claim to have found the root cause of asthma, a breakthrough which could pave the way for a new treatment for the disorder within five years.

Researchers described the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 million people worldwide.

The team used mouse models of asthma and human airway tissue from asthmatic and non-asthmatic people to reach their findings.

Also Read

Researchers also highlight the effectiveness of a class of drugs known as calcilytics in manipulating CaSR to reverse all symptoms associated with the condition.

These symptoms include airway narrowing, airway twitchiness and inflammation - all of which contribute to increased breathing difficulty.

"Our findings are incredibly exciting," said principal investigator, Professor Daniela Riccardi, from Cardiff University School of Biosciences.

"For the first time we have found a link airways inflammation, which can be caused by environmental triggers - such as allergens, cigarette smoke and car fumes - and airways twitchiness in allergic asthma," said Riccardi.

"Our paper shows how these triggers release chemicals that activate CaSR in airway tissue and drive asthma symptoms like airway twitchiness, inflammation, and narrowing. Using calcilytics, nebulised directly into the lungs, we show that it is possible to deactivate CaSR and prevent all of these symptoms," Riccardi added.

Riccardi and her collaborators are now seeking funding to determine the efficacy of calcilytic drugs in treating asthmas that are especially difficult to treat, particularly steroid-resistant and influenza-exacerbated asthma, and to test these drugs in patients with asthma.

The latest breakthrough has provided researchers with the unique opportunity to re-purpose these drugs, potentially accelerating the time it takes for them to be approved for use asthma patients.

"If we can prove that calcilytics are safe when administered directly to the lung in people, then in five years we could be in a position to treat patients and potentially stop asthma from happening in the first place," Riccardi said.

The study was published in Science Translational Medicine journal.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Apr 24 2015 | 7:28 AM IST

Next Story